Lyfegen Company Profile

Background

Overview

Founded in 2018 and headquartered in Basel, Switzerland, Lyfegen HealthTech AG is an independent provider of rebate management software tailored for the healthcare industry. The company's mission is to accelerate the transition from volume-based to value-based healthcare, ensuring that patients have access to innovative therapies at sustainable costs. Lyfegen's platform is utilized by health insurers, governments, hospital payers, and pharmaceutical companies worldwide to streamline complex drug pricing agreements and optimize rebate processes.

Key Strategic Focus

Core Objectives

Value-Based Healthcare Transition: Facilitate the shift from traditional fee-for-service models to value-based payment structures, emphasizing patient outcomes and cost-effectiveness.

Operational Efficiency: Automate and simplify the management of intricate drug pricing agreements to reduce administrative burdens and enhance compliance.

Specialization Areas

Rebate Management: Provide solutions that enable efficient tracking and management of pharmaceutical rebates, ensuring transparency and accuracy.

Data Analytics: Utilize real-world data and machine learning to analyze patient outcomes and financial impacts, supporting informed decision-making.

Key Technologies

Lyfegen Platform: A patent-pending software-as-a-service (SaaS) platform that automates the collection and analysis of patient-level data, facilitating the execution of value-based healthcare agreements.

Drug Pricing Simulator: A robust tool designed to dynamically simulate complex drug pricing scenarios, allowing stakeholders to understand the full financial impact of various pricing models.

Primary Markets

Lyfegen has a significant presence in Europe, North America, and the Middle East, serving over 50 healthcare organizations across eight geographical markets. The platform manages more than 4,000 rebate agreements, tracks over $1 billion in pharmaceutical revenue, and oversees over $0.5 billion in rebates annually.

Financials and Funding

Funding History

Seed Funding (April 2019): Raised CHF 750,000 to develop the Lyfevalue platform and conduct pilot projects in the US, Africa, and Europe.

Additional Funding (September 2020): Secured CHF 2 million to advance value-based healthcare contracting and expand into new markets.

Series A Funding (September 2022): Closed an $8 million round led by aMoon, with participation from APEX Ventures and others, to drive down drug costs and enhance patient access to life-saving medications.

Additional Series A Funding (December 2024): Raised an additional CHF 5 million, led by TX Ventures with participation from aMoon and other institutional investors, to scale the drug rebate management platform globally.

Utilization of Capital

The funds have been allocated to:

Enhancing the Lyfegen platform's capabilities.

Expanding market presence, particularly in the US.

Conducting pilot projects and forming strategic partnerships.

Technological Platform and Innovation

Proprietary Technologies

Lyfegen Platform: A secure, patent-pending SaaS solution that automates the execution of value-based healthcare agreements by collecting and analyzing patient-level data.

Public Drug Agreement Library: A repository of over 7,000 public pricing agreements, providing real-world strategies to guide smarter decisions.

Scientific Methodologies

Data Analytics and Machine Learning: Employs advanced algorithms to analyze real-world data, enabling stakeholders to understand the financial impact of various pricing models and patient outcomes.

Leadership Team

Girisha Fernando, CEO: Co-founder with extensive experience in healthcare and technology, leading Lyfegen's strategic vision and growth.

Michel Mohler, CFO: Co-founder overseeing financial operations and strategic financial planning.

Nico Mros, CXO: Co-founder responsible for customer experience and operational excellence.

Competitor Profile

Market Insights and Dynamics

The global healthcare industry is increasingly adopting value-based payment models to address rising drug costs and improve patient outcomes. The market for innovative and personalized treatments is expanding rapidly, necessitating complex and cost-effective pricing models.

Competitor Analysis

Diameter Health: Develops technology to enable clinical insight through the normalization and enrichment of clinical data.

Tomorrow.io: Provides a weather intelligence platform, indirectly related but indicative of the growing role of data analytics in various sectors.

OneMarketData: Offers data management software solutions, highlighting the competitive landscape in data analytics and management.

Strategic Collaborations and Partnerships

EVERSANA (January 2025): Collaborated to revolutionize drug pricing and access through AI-driven insights, combining data from EVERSANA's NAVLIN platform with Lyfegen's Public Drug Agreement Library.

Johnson & Johnson Switzerland (August 2021): Implemented Lyfegen's platform to support value-based healthcare strategies in collaboration with a leading Swiss hospital.